MA38206B1 - Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées - Google Patents
Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associéesInfo
- Publication number
- MA38206B1 MA38206B1 MA38206A MA38206A MA38206B1 MA 38206 B1 MA38206 B1 MA 38206B1 MA 38206 A MA38206 A MA 38206A MA 38206 A MA38206 A MA 38206A MA 38206 B1 MA38206 B1 MA 38206B1
- Authority
- MA
- Morocco
- Prior art keywords
- hydrazones
- tuberculosis
- pyridyl
- related diseases
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des pyridyl-hydrazones de formule (i), ou des sels, esters, solvates, isomères et promédicaments pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions pharmaceutiques contenant ces composés, à utiliser pour le traitement prophylactique et/ou thérapeutique de la tuberculose et de maladies associées, par exemple, des maladies causées par des mycobactéries non tuberculeuses et/ou par
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT106652A PT106652A (pt) | 2012-11-20 | 2012-11-20 | Piridil hidrazonas para o tratamento de tuberculose e doenças relacionadas |
PCT/PT2013/000068 WO2014081324A1 (fr) | 2012-11-20 | 2013-11-20 | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38206A1 MA38206A1 (fr) | 2017-12-29 |
MA38206B1 true MA38206B1 (fr) | 2019-03-29 |
Family
ID=49876952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38206A MA38206B1 (fr) | 2012-11-20 | 2013-11-20 | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées |
Country Status (15)
Country | Link |
---|---|
US (1) | US9593103B2 (fr) |
EP (2) | EP2922541B1 (fr) |
BR (1) | BR112015011606A2 (fr) |
CY (2) | CY1121861T1 (fr) |
DK (1) | DK2922541T3 (fr) |
ES (2) | ES2899437T3 (fr) |
HR (2) | HRP20211767T1 (fr) |
HU (2) | HUE056531T2 (fr) |
LT (2) | LT3539543T (fr) |
MA (1) | MA38206B1 (fr) |
PL (2) | PL3539543T3 (fr) |
PT (3) | PT106652A (fr) |
RS (2) | RS62579B1 (fr) |
SI (2) | SI3539543T1 (fr) |
WO (1) | WO2014081324A1 (fr) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3716131A1 (de) * | 1987-05-14 | 1988-12-01 | Forsch Borstel Inst Fuer Exper | Substituierte 2-acylpyridin-(alpha)-(n)-hetarylhydrazone sowie diese enthaltende arzneimittel |
US8865901B2 (en) * | 2009-10-02 | 2014-10-21 | Fred Hutchinson Cancer Research Center | Gain-of-function Bcl-2 inhibitors |
EP2311457A1 (fr) * | 2009-10-19 | 2011-04-20 | Forschungszentrum Borstel | Compositions pharmaceutiques pour traiter les infections avec des mycobactéries résistantes aux médicaments |
-
2012
- 2012-11-20 PT PT106652A patent/PT106652A/pt unknown
-
2013
- 2013-11-20 PL PL19167996T patent/PL3539543T3/pl unknown
- 2013-11-20 LT LTEP19167996.8T patent/LT3539543T/lt unknown
- 2013-11-20 HU HUE19167996A patent/HUE056531T2/hu unknown
- 2013-11-20 LT LTEP13811632.2T patent/LT2922541T/lt unknown
- 2013-11-20 ES ES19167996T patent/ES2899437T3/es active Active
- 2013-11-20 HR HRP20211767TT patent/HRP20211767T1/hr unknown
- 2013-11-20 PT PT191679968T patent/PT3539543T/pt unknown
- 2013-11-20 RS RS20211433A patent/RS62579B1/sr unknown
- 2013-11-20 DK DK13811632.2T patent/DK2922541T3/da active
- 2013-11-20 ES ES13811632T patent/ES2741434T3/es active Active
- 2013-11-20 EP EP13811632.2A patent/EP2922541B1/fr active Active
- 2013-11-20 SI SI201331949T patent/SI3539543T1/sl unknown
- 2013-11-20 SI SI201331543T patent/SI2922541T1/sl unknown
- 2013-11-20 US US14/646,197 patent/US9593103B2/en active Active
- 2013-11-20 EP EP19167996.8A patent/EP3539543B1/fr active Active
- 2013-11-20 RS RSP20191006 patent/RS59224B1/sr unknown
- 2013-11-20 PT PT13811632T patent/PT2922541T/pt unknown
- 2013-11-20 PL PL13811632T patent/PL2922541T3/pl unknown
- 2013-11-20 WO PCT/PT2013/000068 patent/WO2014081324A1/fr active Application Filing
- 2013-11-20 BR BR112015011606A patent/BR112015011606A2/pt not_active Application Discontinuation
- 2013-11-20 MA MA38206A patent/MA38206B1/fr unknown
- 2013-11-20 HU HUE13811632A patent/HUE045502T2/hu unknown
-
2019
- 2019-08-02 HR HRP20191402 patent/HRP20191402T1/hr unknown
- 2019-08-06 CY CY20191100833T patent/CY1121861T1/el unknown
-
2021
- 2021-11-26 CY CY20211101030T patent/CY1124836T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
SI2922541T1 (sl) | 2019-10-30 |
PL2922541T3 (pl) | 2019-10-31 |
US9593103B2 (en) | 2017-03-14 |
ES2741434T3 (es) | 2020-02-11 |
LT2922541T (lt) | 2019-09-25 |
EP3539543B1 (fr) | 2021-09-01 |
PT106652A (pt) | 2014-05-20 |
SI3539543T1 (sl) | 2022-01-31 |
DK2922541T3 (da) | 2019-08-12 |
CY1121861T1 (el) | 2020-07-31 |
RS59224B1 (sr) | 2019-10-31 |
MA38206A1 (fr) | 2017-12-29 |
EP2922541B1 (fr) | 2019-05-22 |
PL3539543T3 (pl) | 2022-01-10 |
US20150284374A1 (en) | 2015-10-08 |
CY1124836T1 (el) | 2022-11-25 |
LT3539543T (lt) | 2021-12-27 |
ES2899437T3 (es) | 2022-03-11 |
RS62579B1 (sr) | 2021-12-31 |
HRP20191402T1 (hr) | 2019-11-15 |
PT3539543T (pt) | 2021-11-22 |
HRP20211767T1 (hr) | 2022-02-18 |
WO2014081324A1 (fr) | 2014-05-30 |
PT2922541T (pt) | 2019-08-26 |
BR112015011606A2 (pt) | 2017-07-11 |
EP2922541A1 (fr) | 2015-09-30 |
HUE045502T2 (hu) | 2019-12-30 |
HUE056531T2 (hu) | 2022-02-28 |
EP3539543A1 (fr) | 2019-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
MA42410B1 (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
NZ708593A (en) | Novel pyrazole derivative | |
MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
MA37886B1 (fr) | Nouvelles pyridinones bicycliques | |
MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
MA38810A1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
MA34746B1 (fr) | Dérivés de diphénylamine : utilisations, procédés de synthèse et compositions pharmaceutiques | |
MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
MA38206B1 (fr) | Pyridyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
MA38207A2 (fr) | Quinolyl-hydrazones pour le traitement de la tuberculose et de maladies associées | |
MA44383B1 (fr) | Un derivé de 4-(3-pyrazolylamino)-benzimidazole en tant qu'inhibiteur de jak1 pour le traitement du cancer | |
TN2014000371A1 (fr) | Dérivés macrocycliques pour le traitement de maladies prolifératives |